替吉奥联合多西他赛方案治疗晚期及复发性胃癌的近期疗效观察  

Clinical observation of S-1 combined with docetaxel in the treatment of patients with advanced or recurrent gastric cancer

作　　者：向其德[1] 覃事鹏 谭力[1] 林绍定 

机构地区：[1]湖南省怀化市第三人民医院肿瘤血液科,418000

出　　处：《中国老年保健医学》2013年第6期46-47,共2页Chinese Journal of Geriatric Care

摘　　要：目的：观察替吉奥联合多西他赛方案治疗晚期及复发性胃癌的近期疗效及不良反应。方法对22例晚期及复发性胃癌采用替吉奥胶囊（维康达）80mg/m2，分2次口服，d1～d14；多西他赛75mg/m2，静脉滴注1小时，d1；21天为1周期，连用2个周期后评价疗效和不良反应。结果22例均完成2周期以上化疗，均可评价，其中2例完全缓解（ CR ），10例部分缓解（ PR），7例稳定（ SD），3例进展（ PD），总有效率（ CR＋PR）54.5％。主要不良反应为胃肠道反应、骨髓抑制，均较轻，未影响治疗。结论替吉奥联合多西他赛方案治疗晚期及复发性胃癌的近期疗效较好，不良反应可以耐受，值得临床进一步研究。Objective To study the short-term efficacy and toxicities of S -1 plus docetaxel in the treatment of patients with advanced or recurrent gastric cancer.Methods 22 patients with advanced or recurrent gastric carcinoma were treated with S -1 plus docetaxel.The chemotherapy include 75mg/m2 of docetaxel intravenously in 1 hour in the first day,and 40mg/m2 of S-1 bid for consecutive 14 days.The treatment was repeated every 21 days.The efficacy and toxicities were evaluated after 2 cycles of chemother-apy.Results There were 2 patients with complete response （ CR） ,10 patients with partial response （ PR） ,7 patients with stable dis-ease（SD）and 3 patients with progression disease （PD）.The overall response rate was 54.5%.Main adverse events were gastrointes-tinal reaction,myelosuppression,which were mild and tolerable.Conclusion The short -term efficacy and toxicities of S -1 plus docetaxel is promising and the toxicities are mild and tolerable.

关 键 词：胃癌 替吉奥 多西他赛 联合化疗 

分 类 号：R735.2[医药卫生—肿瘤]